ADARRC

About ADARRC

This author has not yet filled in any details.
So far ADARRC has created 35 blog entries.

How do ibuprofen, ketorolac, and diclofenac compare for the treatment of acute, nonradicular low back pain in adults?

2022-05-12T11:03:57+04:00

How do ibuprofen, ketorolac, and diclofenac compare for the treatment of acute, nonradicular low back pain in adults? This study found no differences among ibuprofen, ketorolac, and diclofenac in the primary outcome of overall clinical improvement at 5 days in adults presenting to the emergency department with acute, nonradicular low back pain. Some of the secondary outcomes favored ketorolac, however, leaving open the possibility that ketorolac is superior to ibuprofen and/or diclofenac. As the saying goes, "Absence of proof is not proof of absence." Irizarry E, Restivo A, Salama M, et al. A randomized controlled trial of ibuprofen versus ketorolac [...]

How do ibuprofen, ketorolac, and diclofenac compare for the treatment of acute, nonradicular low back pain in adults?2022-05-12T11:03:57+04:00

Are platelet-rich plasma injections effective for alleviating pain and improving function in adults with symptomatic ankle osteoarthritis?

2022-05-12T11:01:39+04:00

Are platelet-rich plasma injections effective for alleviating pain and improving function in adults with symptomatic ankle osteoarthritis? This study found no evidence that supports a benefit of PRP injections compared with saline placebo injections for improving function or reducing pain in adults with symptomatic ankle osteoarthritis. Paget LDA, Reurink G, de Vos RJ, et al, for the PRIMA Study Group. Effect of platelet-rich plasma injections vs placebo on ankle symptoms and function in patients with ankle osteoarthritis. A randomized clinical trial. JAMA 2021;326(16):1595-1605.

Are platelet-rich plasma injections effective for alleviating pain and improving function in adults with symptomatic ankle osteoarthritis?2022-05-12T11:01:39+04:00

Recurrent herpes zoster more common in women, younger adults, and the immunosuppressed

2022-03-28T10:37:26+04:00

What is the incidence and timing of recurrent herpes zoster in older adults? The incidence of recurrent herpes zoster is comparable with the incidence of a first episode zoster infection, supporting the benefit of vaccination for individuals with a history of previous herpes zoster. See the synopsis for specific recurrent incidence risks based on age, sex, and time following initial infection. Qian J, Macartney K, Heywood AE, Sheridan S, Liu B. Risk of recurrent herpes zoster in a population-based cohort study of older adults. J Am Acad Dermatol 2021;85(3):611-618.

Recurrent herpes zoster more common in women, younger adults, and the immunosuppressed2022-03-28T10:37:26+04:00

Evidence of benefit is lacking for low back pain relief with muscle relaxants

2022-03-28T10:32:59+04:00

Do muscle relaxants provide relief for nonspecific lower back pain? Stick with nonsteroidal anti-inflammatories for the treatment of low back pain. Despite being used for almost 50 years to treat low back pain, the evidence supporting benzodiazepine or non-benzodiazepine “muscle relaxants” is of low certainty. None of the treatments will produce a clinically important difference over placebo treatment. Cashin AG, Folly T, Bagg MK, et al. Efficacy, acceptability, and safety of muscle relaxants for adults with non-specific low back pain: systematic review and meta-analysis. BMJ 2021;374:n1446.

Evidence of benefit is lacking for low back pain relief with muscle relaxants2022-03-28T10:32:59+04:00

Fluvoxamine decreases hospitalizations in high-risk adults with COVID-19 (TOGETHER)

2021-12-23T10:35:17+04:00

Is fluvoxamine effective in preventing hospitalizations in high-risk adults with COVID-19? In this study, compared with placebo, fluvoxamine decreased hospitalizations in high-risk symptomatic adults with COVID-19. Reis G, dos Santos Moreira-Silva EA, Silva DCM, et al, for the TOGETHER investigators. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Glob Health 2021;S2214-109X(21)00448-4.

Fluvoxamine decreases hospitalizations in high-risk adults with COVID-19 (TOGETHER)2021-12-23T10:35:17+04:00

Booster with Pfizer mRNA vaccine significantly reduces likelihood of infection and severe illness due to COVID-19 in adults 60+

2021-12-23T09:53:23+04:00

Does a booster dose provide clinical benefit against symptomatic infection and serious illness due to COVID-19 in persons 60 years and older who are fully vaccinated with the Pfizer-BioNTech vaccine? A booster (third) dose of the BNT162b2 mRNA vaccine from Pfizer-BioNTech provides significant additional protection against both infection and serious illness. (LOE = 2b) Bar-On YM, Goldberg Y, Mandel M, et al. Protection of BNT162b2 vaccine booster against Covid-19 in Israel. N Engl J Med 2021;385(15):1393-1400.

Booster with Pfizer mRNA vaccine significantly reduces likelihood of infection and severe illness due to COVID-19 in adults 60+2021-12-23T09:53:23+04:00

Evidence of benefit is lacking for low back pain relief with muscle relaxants

2021-12-22T14:02:09+04:00

Do muscle relaxants provide relief for nonspecific lower back pain? Stick with nonsteroidal anti-inflammatories for the treatment of low back pain. Despite being used for almost 50 years to treat low back pain, the evidence supporting benzodiazepine or non-benzodiazepine “muscle relaxants” is of low certainty. None of the treatments will produce a clinically important difference over placebo treatment. Cashin AG, Folly T, Bagg MK, et al. Efficacy, acceptability, and safety of muscle relaxants for adults with non-specific low back pain: systematic review and meta-analysis. BMJ 2021;374:n1446.

Evidence of benefit is lacking for low back pain relief with muscle relaxants2021-12-22T14:02:09+04:00

Recurrent herpes zoster more common in women, younger adults, and the immunosuppressed

2021-11-30T15:08:32+04:00

What is the incidence and timing of recurrent herpes zoster in older adults? The incidence of recurrent herpes zoster is comparable with the incidence of a first episode zoster infection, supporting the benefit of vaccination for individuals with a history of previous herpes zoster. See the synopsis for specific recurrent incidence risks based on age, sex, and time following initial infection. Qian J, Macartney K, Heywood AE, Sheridan S, Liu B. Risk of recurrent herpes zoster in a population-based cohort study of older adults. J Am Acad Dermatol 2021;85(3):611-618.

Recurrent herpes zoster more common in women, younger adults, and the immunosuppressed2021-11-30T15:08:32+04:00

There is limited data on ivermectin in patients with COVID-19

2021-11-30T14:53:25+04:00

Does ivermectin decrease mortality among persons hospitalized with COVID-19? Although the data suggest that ivermectin decreases mortality among persons hospitalized with COVID-19, the messiness of the comparison groups and the concerns over data veracity indicate that more rigorous study is needed. Hill A, Garratt A, Levi J, et al. Meta-analysis of randomized trials of ivermectin to treat SARS-CoV-2 infection. Open Forum Infect Dis 2021:ofab358. Erratum: Hill A, Garratt A, Levi J, et al. Erratum: expression of concern: "Meta-analysis of randomized trials of ivermectin to treat SARS-CoV-2 infection." Open Forum Infect Dis 2021;8(8):ofab394. [...]

There is limited data on ivermectin in patients with COVID-192021-11-30T14:53:25+04:00

Pregnant women who become ill with COVID-19 are more likely to die and have adverse perinatal and neonatal outcomes

2021-11-30T14:51:15+04:00

Do pregnant women who become ill with COVID-19 have worse outcomes than pregnant women who are not infected with COVID-19? Pregnant women who become ill with COVID-19 are more likely to die and have adverse perinatal and neonatal outcomes than pregnant women who are uninfected with COVID-19. Villar J, Ariff S, Gunier RB, et al. Maternal and neonatal morbidity and mortality among pregnant women with and without COVID-19 infection: The INTERCOVID Multinational Cohort Study. JAMA Pediatr 2021;175(8):817-826.

Pregnant women who become ill with COVID-19 are more likely to die and have adverse perinatal and neonatal outcomes2021-11-30T14:51:15+04:00
Go to Top